NEW

Switch to Dark

Pricing

Learn

ABT - Abbott Laboratories

261

$107.19

-$1.30 (-1.198%)

At market close

$107.40

$0.21 (0.191%)

After Hours 3/19/26, 10:19 PM

3.79/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

ABT

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$186.26B

Industry

Health Care

EPS (TTM)

$3.74

P/E (TTM)

28.55

Div & Yield

$2.52 (2.35%)

FCF Payout Ratio

59.22%

P/S (TTM)

4.20

P/B

3.57

Diluted Shares

1.74B

Ex-Dividend

2026-04-15

Next Earnings

04-14

Forward P/E

18.89

Payout Ratio

67.12%

P/FCF (TTM)

25.19

FCF Yield

3.97%

Earnings Yield

3.50%

52 Week Range

Score Card

Explore Scores Tab

3.79

Good

Abbott Laboratories has grown revenue at 5.67% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 16.68%, which suggests the company is very profitable.

Valuation Model

Key Score

5.00

Very Good

Management

3.00

Average

Growth

1.00

Very Bad

Profitability

3.00

Average

Fin. Health

2.00

Bad

Dividends

5.00

Very Good

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form ARS

Unknown Form Type

Filed on 2026-03-13 16:01:48

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-13 16:01:21

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-13 16:00:23

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-09 16:21:32

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 20:20:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 20:15:27

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 20:10:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 20:06:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 20:00:16

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:55:24

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:48:46

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:44:17

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$165.90

54.8%

Avg:

$136.02

26.9%

Low:

$114.13

6.5%

(% change is relative to the current stock price: $107.19)

Analyst Recommendations

Go to Analyst Tab

4.00

Good

29%

Strong Buy (10)

43%

Buy (15)

29%

Hold (10)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.abbott.com
Address
100 Abbott Park Road, Abbot Park, ABBOTT PARK ILLINOIS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1800

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.

IPO Date

1937-03-01

Industry

Health Care

Total Employees

115,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services